YM060
Sponsors
Astellas Pharma Inc
Conditions
Diarrhea-predominant Irritable Bowel SyndromeHealthyIrritable Bowel SyndromePlasma Concentration of YM060
Phase 1
A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet
CompletedNCT01392794
Start: 2011-04-30End: 2011-05-31Updated: 2011-07-13
A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake
CompletedNCT01394653
Start: 2011-07-31End: 2011-08-31Updated: 2011-10-12
Phase 2
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
CompletedNCT00189813
Start: 2005-03-31End: 2005-12-31Updated: 2014-08-28
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
CompletedNCT01274000
Start: 2010-11-30End: 2011-10-31Updated: 2015-10-12
Phase 3
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
CompletedNCT00189696
Updated: 2015-10-12
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
CompletedNCT01736423
Start: 2012-09-30End: 2014-05-31Updated: 2015-10-12
A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)
CompletedNCT01870895
Start: 2013-02-28End: 2014-02-28Updated: 2015-10-12